Medicare locks in high prices for wound products, bars clinical review

What it does

This bill creates a new Medicare payment category for skin substitute products (cellular or tissue-based wound treatments) from 2027–2030, setting a fixed reimbursement rate of $457 per square centimeter and requiring products to be domestically sourced, harvested, and manufactured. It imposes strict oversight on providers—including prepayment review, prior authorization, and certification requirements—and bars Medicare from denying coverage based solely on clinical evidence during 2027. The bill benefits wound-care manufacturers and certified providers who meet domestic-sourcing rules, while imposing compliance costs and payment floors on the industry.

Why we flagged it

The bill's operative mechanism is a fixed reimbursement rate and minimum provider cost floor for a specific product category, combined with a domestic-sourcing requirement that restricts supply and a coverage guarantee that insulates the category from clinical-evidence review during 2027. This is a hybrid of price-setting and supply-chain protectionism.

What the text implies

• The $457/sq cm payment rate and $342.75/sq cm cost floor are set by statute without reference to actual production costs, clinical outcomes, or competitive pricing—locking in margins for 4 years and creating a de facto price floor that may inflate Medicare spending.
• The domestic-sourcing requirement (all harvesting, processing, manufacturing in US; all human material from US citizens/permanent residents) may exclude lower-cost international products and reduce supply diversity, potentially raising prices for patients and Medicare.
• The 2027 coverage guarantee—barring Medicare from denying coverage based on clinical evidence alone—creates a one-year immunity window for products that may lack robust efficacy data, shifting risk to the program.
• Prepayment review and prior authorization target 'specified providers' (including those with 15%+ of claims in skin substitutes), creating a two-tier system where high-volume providers face automatic scrutiny regardless of fraud signals.
• The 'reasonable and necessary' definition (greater of 350 sq cm or 120% of wound size) may incentivize overuse and wastage reimbursement, inflating per-patient costs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain potential access to skin substitute products with Medicare coverage guarantees and fraud oversight, but the bill locks in a high fixed payment rate ($457/sq cm) and a minimum provider cost floor ($342.75/sq cm) that may inflate Medicare spending and premiums without evidence that these prices reflect actual clinical value or cost of production. The domestic-sourcing mandate may limit product availability and choice.

Who stands to gain

• skin substitute product manufacturers (domestic only)
• certified wound-care providers and specialists
• wound-care clinics and hospitals with certified staff

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), Food and Drug Administration (FDA), American Association of Tissue Banks, American Board of Wound Management, Wound, Ostomy and Continence Nursing Certification Board, National Alliance of Wound Care and Ostomy, American Foot Care Nurses Association, Office of Inspector General (OIG), Federal Supplementary Medical Insurance Trust Fund, Medicare Administrative Contractors

Where it stands

• Jul 27, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 27, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.